EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kiadis Pharma NV's enterprise value is €220.73 Mil.
Kiadis Pharma NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was €17.50 Mil. Therefore, Kiadis Pharma NV's EV-to-Revenue for today is 12.61.
The historical rank and industry rank for Kiadis Pharma NV's EV-to-Revenue or its related term are showing as below:
XAMS:KDS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 11.04 Med: 11.34 Max: 11.48
Current: 12.61
During the past 9 years, the highest EV-to-Revenue of Kiadis Pharma NV was 11.48. The lowest was 11.04. And the median was 11.34.
XAMS:KDS's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.68
vs XAMS:KDS: 12.61
As of today (2024-04-26), Kiadis Pharma NV's stock price is €5.46.
Kiadis Pharma NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was €0.44. Therefore, Kiadis Pharma NV's PS Ratio for today is 12.52.
Kiadis Pharma NV EV-to-Revenue Historical Data
The historical data trend for Kiadis Pharma NV's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kiadis Pharma NV's EV-to-Revenue
For the Biotechnology subindustry, Kiadis Pharma NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiadis Pharma NV's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Kiadis Pharma NV's EV-to-Revenue falls into.
Kiadis Pharma NV's current Enterprise Value is €220.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kiadis Pharma NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was €17.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiadis Pharma NV's share price for today is €5.46.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2020 was €0.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiadis Pharma NV EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Kiadis Pharma NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XAMS:KDS has been successfully added to your 